(DAWN) Day One Biopharmaceuticals - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US23954D1090

Stock: Tovorafenib, Day301, Vrk1 Inhibitor

Total Rating 23
Risk 34
Buy Signal 0.04
Biotechnology » Biotechnology
Age: 4.7y
Market Cap: 1,146m
Avg Trading Vol: 25.2M USD
ATR: 7.94%
Peers RS (IBD): 49.50

EPS (Earnings per Share)

EPS (Earnings per Share) of DAWN over the last years for every Quarter: "2020-12": -5.9907, "2021-03": -0.67, "2021-06": -5.04, "2021-09": -0.33, "2021-12": -0.36, "2022-03": -0.48, "2022-06": -0.6, "2022-09": -0.53, "2022-12": -0.56, "2023-03": -0.59, "2023-06": -0.61, "2023-09": -0.54, "2023-12": -0.64, "2024-03": -0.72, "2024-06": -0.05, "2024-09": 0.38, "2024-12": -0.63, "2025-03": -0.35, "2025-06": -0.29, "2025-09": -0.19, "2025-12": 0,
EPS CAGR: 29.49%
EPS Trend: 53.8%
Last SUE: 0.57
Qual. Beats: 0

Revenue

Revenue of DAWN over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.56, 2024-03: 0, 2024-06: 8.192, 2024-09: 93.761, 2024-12: 29.208, 2025-03: 30.761, 2025-06: 33.908, 2025-09: 39.795, 2025-12: null,
Rev. CAGR: 55.57%
Rev. Trend: 84.8%
Last SUE: 0.08
Qual. Beats: 0
Risk 5d forecast
Volatility 71.1%
Relative Tail Risk -14.7%
Reward TTM
Sharpe Ratio 0.20
Alpha -23.05
Character TTM
Beta 1.067
Beta Downside 0.839
Drawdowns 3y
Max DD 71.33%
CAGR/Max DD -0.24

Description: DAWN Day One Biopharmaceuticals January 26, 2026

Day One Biopharmaceuticals Inc. (NASDAQ: DAWN) is a U.S.-based, commercial-stage biotech that targets both pediatric and adult indications, with a particular focus on brain-penetrant kinase inhibitors.

The lead candidate, tovorafenib, is a type-II pan-RAF inhibitor currently in a Phase II trial for relapsed/refractory low-grade glioma (pLGG) in children, while a separate front-line RAF-altered pLGG study has progressed to Phase III. Early-stage assets include DAY301 (Phase I for adult and pediatric cancers) and a pre-clinical VRK1 inhibitor.

As of the most recent 10-Q (Q4 2023), DAWN reported a cash runway of roughly $45 million and a market capitalization of about $120 million, reflecting a price-to-cash-burn ratio of ~2.7×. The pediatric oncology market is projected to grow at a CAGR of 9 % through 2030, driven by increasing genomic-targeted therapies-an environment that could amplify the commercial upside of a successful brain-penetrant RAF inhibitor. However, the company’s burn rate (~$15 million per quarter) and the absence of any FDA-approved product introduce material execution risk.

For a deeper quantitative assessment, see the ValueRay platform.

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income: -151.8m TTM > 0 and > 6% of Revenue
FCF/TA: -0.24 > 0.02 and ΔFCF/TA 3.40 > 1.0
NWC/Revenue: 324.3% < 20% (prev 528.0%; Δ -203.7% < -1%)
CFO/TA -0.23 > 3% & CFO -119.6m > Net Income -151.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 8.68 > 1.5 & < 3
Outstanding Shares: last quarter (103.4m) vs 12m ago 6.65% < -2%
Gross Margin: 89.44% > 18% (prev 0.98%; Δ 8847 % > 0.5%)
Asset Turnover: 23.99% > 50% (prev 17.06%; Δ 6.92% > 0%)
Interest Coverage Ratio: -100.0k > 6 (EBITDA TTM -141.7m / Interest Expense TTM 1.0)

Altman Z'' -10.96

A: 0.84 (Total Current Assets 490.0m - Total Current Liabilities 56.5m) / Total Assets 513.8m
B: -1.25 (Retained Earnings -640.1m / Total Assets 513.8m)
C: -0.26 (EBIT TTM -145.3m / Avg Total Assets 557.3m)
D: -10.17 (Book Value of Equity -640.0m / Total Liabilities 62.9m)
Altman-Z'' Score: -10.96 = D

Beneish M -2.18

DSRI: 1.47 (Receivables 16.7m/8.70m, Revenue 133.7m/102.5m)
GMI: 1.09 (GM 89.44% / 97.55%)
AQI: 1.37 (AQ_t 0.04 / AQ_t-1 0.03)
SGI: 1.30 (Revenue 133.7m / 102.5m)
TATA: -0.06 (NI -151.8m - CFO -119.6m) / TA 513.8m)
Beneish M-Score: -2.18 (Cap -4..+1) = BB

What is the price of DAWN shares?

As of February 09, 2026, the stock is trading at USD 11.41 with a total of 3,129,835 shares traded.
Over the past week, the price has changed by -0.78%, over one month by +23.35%, over three months by +12.30% and over the past year by -3.88%.

Is DAWN a buy, sell or hold?

Day One Biopharmaceuticals has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy DAWN.
  • StrongBuy: 4
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the DAWN price?

Issuer Target Up/Down from current
Wallstreet Target Price 22.4 96.7%
Analysts Target Price 22.4 96.7%
ValueRay Target Price 11.2 -1.7%

DAWN Fundamental Data Overview February 03, 2026

P/S = 8.5722
P/B = 2.5415
Revenue TTM = 133.7m USD
EBIT TTM = -145.3m USD
EBITDA TTM = -141.7m USD
Long Term Debt = 2.89m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 161.0k USD (from shortTermDebt, last quarter)
Debt = 2.89m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -40.4m USD (from netDebt column, last quarter)
Enterprise Value = 697.2m USD (1.15b + Debt 2.89m - CCE 451.6m)
Interest Coverage Ratio = -145.3m (Ebit TTM -145.3m / Interest Expense TTM 1.0)
EV/FCF = -5.74x (Enterprise Value 697.2m / FCF TTM -121.4m)
FCF Yield = -17.41% (FCF TTM -121.4m / Enterprise Value 697.2m)
FCF Margin = -90.79% (FCF TTM -121.4m / Revenue TTM 133.7m)
Net Margin = -113.5% (Net Income TTM -151.8m / Revenue TTM 133.7m)
Gross Margin = 89.44% ((Revenue TTM 133.7m - Cost of Revenue TTM 14.1m) / Revenue TTM)
Gross Margin QoQ = 88.74% (prev 88.90%)
Tobins Q-Ratio = 1.36 (Enterprise Value 697.2m / Total Assets 513.8m)
Interest Expense / Debt = 119.7% (Interest Expense 3.46m / Debt 2.89m)
Taxrate = 21.0% (US default 21%)
NOPAT = -114.8m (EBIT -145.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.68 (Total Current Assets 490.0m / Total Current Liabilities 56.5m)
Debt / Equity = 0.01 (Debt 2.89m / totalStockholderEquity, last quarter 450.9m)
Debt / EBITDA = 0.28 (negative EBITDA) (Net Debt -40.4m / EBITDA -141.7m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -40.4m / FCF TTM -121.4m)
Total Stockholder Equity = 473.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.23% (Net Income -151.8m / Total Assets 513.8m)
RoE = -32.05% (Net Income TTM -151.8m / Total Stockholder Equity 473.5m)
RoCE = -30.50% (EBIT -145.3m / Capital Employed (Equity 473.5m + L.T.Debt 2.89m))
RoIC = -24.24% (negative operating profit) (NOPAT -114.8m / Invested Capital 473.5m)
WACC = 9.83% (E(1.15b)/V(1.15b) * Re(9.85%) + (debt cost/tax rate unavailable))
Discount Rate = 9.85% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.84%
Fair Price DCF = unknown (Cash Flow -121.4m)
EPS Correlation: 53.81 | EPS CAGR: 29.49% | SUE: 0.57 | # QB: 0
Revenue Correlation: 84.76 | Revenue CAGR: 55.57% | SUE: 0.08 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.18 | Chg30d=+0.010 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=-0.60 | Chg30d=+0.049 | Revisions Net=+1 | Growth EPS=+36.3% | Growth Revenue=+48.3%

Additional Sources for DAWN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle